Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Bristol-Myers Squibb and Innate Pharma Announce Global License Agreement for an Investigational Immuno-Oncology Biologic

By Pharmaceutical Processing | July 7, 2011

 

Bristol-Myers Squibb Company and Innate Pharma S.A. have
announced a global agreement for the development and commercialization of
IPH2102, a novel antibody in Phase I development for the treatment of cancer.

Under the terms of the agreement, Innate Pharma will grant
to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture and
commercialize IPH2102 and related compounds blocking KIR receptors. The
agreement covers all potential indications for IPH2102. Innate Pharma will
continue to develop IPH2102 in acute myeloid leukemia (AML) through to the end
of Phase II. Innate Pharma will also provide pre-clinical support for the
development of IPH2102.

Bristol-Myers Squibb will fund the development of IPH2102,
make an upfront payment of $35 million and additional payments of up to $430 million,
depending on the achievement of pre-specified milestones during the development
and commercialization period, as well as pre-specified tiered double-digit
royalty payments on worldwide net sales.

“Bristol-Myers Squibb is dedicated to helping patients
prevail over cancer,” said Francis Cuss, senior vice president, Research, Bristol-Myers
Squibb. “To help us in this mission, we are very pleased to join forces
with Innate Pharma which has developed a deep understanding of the immune
system. Working together we have the opportunity to develop IPH2102, a
potential first-in-class biologic that may be able to harness a patient’s
immune system in the fight against cancer.” “Bristol-Myers Squibb’s
String of Pearls strategy seeks to establish collaborations with leading
innovator companies across the globe” said Mike Seeley, general manager, France,
Bristol-Myers Squibb. “We are excited to establish an important such
collaboration in France
with Innate Pharma, a pioneer in the field of innate immunity. This collaboration
highlights our commitment to France,
the French biotech community and to immuno-oncology, an area in which
Bristol-Myers Squibb has developed a robust pipeline including
ipilimumab.” “This agreement is the largest biotech licensing deal
ever signed in France.
Entering such a collaboration with Bristol-Myers Squibb gives Innate Pharma a
strong validation of the key concepts of its science”, said Herve Brailly,
Chief Executive Officer, Innate Pharma. “Bristol Myers Squibb is a global
leader in the field of immuno-oncology and therefore the best possible partner
to fully realize the potential of IPH2102 and we look forward to this
collaboration.”  

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE